

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

C57BL/6-Tg(TcraTcrb)1100Mjb/Crl

RRID:IMSR_CRL:642

Type: Organism

Proper Citation

RRID:IMSR_CRL:642

Organism Information

URL: <http://www.criver.com/products-services/basic-research/find-a-model/ot-1-mouse>

Proper Citation: RRID:IMSR_CRL:642

Description: Mus musculus with name C57BL/6-Tg(TcraTcrb)1100Mjb/Crl from IMSR.

Species: Mus musculus

Notes: gene symbol note: T cell receptor beta chain|T cell receptor alpha chain;
unclassified: Tcrb|Tcra

Affected Gene: T cell receptor beta chain|T cell receptor alpha chain

Genomic Alteration: |transgene insertion 1100; Michael J Bevan

Catalog Number: CRL:642

Database: Charles River Laboratories

Database Abbreviation: CRL

Availability: live

Organism Name: C57BL/6-Tg(TcraTcrb)1100Mjb/Crl

Record Creation Time: 20250513T062410+0000

Record Last Update: 20260725T053146+0000

Ratings and Alerts

No rating or validation information has been found for C57BL/6-Tg(TcraTcrb)1100Mjb/Crl.

No alerts have been found for C57BL/6-Tg(TcraTcrb)1100Mjb/Crl.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Charles River Laboratories

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Kang J, et al. (2025) Controlling intracellular processing to enhance spherical nucleic acid immune stimulation. *Proceedings of the National Academy of Sciences of the United States of America*, 122(45), e2409554122.

Song Z, et al. (2025) CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice. *Cancer immunology research*, 13(8), 1246.

Bi G, et al. (2025) Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. *Nature communications*, 16(1), 8181.

El Hebieshy AF, et al. (2025) Site-directed multivalent conjugation of antibodies to ubiquitinated payloads. *Nature biomedical engineering*, 9(7), 1101.

Wijffjes Z, et al. (2025) Co-delivery of antigen and adjuvant by site-specific conjugation to dendritic cell-targeted Fab fragments potentiates T cell responses. *RSC chemical biology*, 6(6), 948.

de Dreu A, et al. (2025) Engineering Fusion Proteins for Nanomedicine-Based Cytokine Therapy. *Bioconjugate chemistry*, 36(8), 1698.

Lian W, et al. (2024) Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion. *International journal of biological sciences*, 20(1), 137.

Paloja K, et al. (2024) Balancing the Nanoscale Organization in Multivalent Materials for Functional Inhibition of the Programmed Death-1 Immune Checkpoint. *ACS nano*, 18(2), 1381.

Jäger E, et al. (2024) pH and ROS Responsiveness of Polymersome Nanovaccines for Antigen and Adjuvant Codelivery: An In Vitro and In Vivo Comparison. *Biomacromolecules*, 25(3), 1749.

Pallavicini I, et al. (2024) LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness. *Nature communications*, 15(1), 7366.

Weiss L, et al. (2023) Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis. *ACS nano*, 17(13), 12101.

Gao Y, et al. (2023) Implication of 99mTc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells. *Journal for immunotherapy of cancer*, 11(3).

Matthe DM, et al. (2023) Novel T cell/organoid culture system allows ex vivo modeling of intestinal graft-versus-host disease. *Frontiers in immunology*, 14, 1253514.

Marin I, et al. (2023) Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity. *Cancer discovery*, 13(2), 410.

Casares N, et al. (2023) Improvement of cognitive function in wild-type and Alzheimer's disease mouse models by the immunomodulatory properties of menthol inhalation or by depletion of T regulatory cells. *Frontiers in immunology*, 14, 1130044.

Pylaeva E, et al. (2022) During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. *Cell reports*, 40(7), 111171.

Linke A, et al. (2022) Antigen Cross-Presentation by Murine Proximal Tubular Epithelial Cells Induces Cytotoxic and Inflammatory CD8+ T Cells. *Cells*, 11(9).

Gargaro M, et al. (2022) Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. *Immunity*, 55(6), 1032.

Nassal JP, et al. (2022) Differential axonal trafficking of Neuropeptide Y-, LAMP1-, and RAB7-tagged organelles in vivo. *eLife*, 11.

Sum E, et al. (2022) The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. *Journal for immunotherapy of cancer*, 10(3).